Brachytherapy firm Theragenics continues to expand its distribution channels. Just days after announcing an agreement with Nycomed Amersham, the Buford, GA-based firm has signed on Imagyn Medical Technologies as a distributor. Imagyn is a minimally invasive and general surgery product provider
Irvine, CA-based Imagyn has signed a five-year, nonexclusive distribution agreement for Theragenics’ TheraSeed, a palladium-103 brachytherapy seed for the treatment of prostate cancer and other solid, localized cancerous tumors. Imagyn will be able to distribute TheraSeed in the U.S., Canada, and Puerto Rico.
TheraSeed will serve as a complement to Imagyn’s isoSTAR, an iodine-125 seed provided to the company by International Isotopes, according to Imagyn chairman, president, and CEO Charles Laverty.
By AuntMinnie.com staff writersSeptember 22, 2000
Related Reading
Nycomed set to distribute TheraSeed, September 20, 2000
Copyright © 2000 AuntMinnie.com
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)
